Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 334 in Stable Angina: Effect on Treadmill Exercise Time
2015-002322-40Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stable angina and migraine comparing AMG 334 with Placebo (2 arms). Primary endpoint: Change from baseline in total exercise time (TET). Started Oct 2015; status: completed.
02
Drugs
erenumab
03
Conditions
stable anginamigraine
Beyond the preview
Go deeper on 2015-002322-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002322-40.